Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R)

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 6, 2010, Pages 1905-1909

  Vrudhula, Vivekananda M ^a   Dasgupta, Bireshwar ^a   Pin, Sokhom S ^a   Burris, Kevin D ^a   Balanda, Lynn A ^a   Fung, Lawrence K ^a   Fiedler, Tracey ^a   Browman, Kaitlin E ^a   Taber, Matthew T ^a   Zhang, Jie ^a   Macor, John E ^a   Dubowchik, Gene M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

CRF Anxiolytic; CRF1R; Tetrahydroimidazopyrimidine

Indexed keywords

CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; TETRAHYDROIMIDAZOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYCLIZATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DESIGN; DRUG PENETRATION; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; MOUSE; NONHUMAN; RECEPTOR AFFINITY; TRANQUILIZING ACTIVITY;

ANIMALS; CYCLIZATION; DRUG DESIGN; MICE; PYRIMIDINES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 77549087249     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.127     Document Type: Article

References (22)

1. In: Miller M. (Ed). Brain Facts. A Primer on Brain and Nervous System. Chapter on Stress (2008), Publication of Society for Neuroscience 31-33. http://www.sfn.org Can be accessed at www.sfn.org
2. Vale W., Spiess J., Rivier C., and Rivier J. Science 213 (1981) 1394
3. Owens M.J., and Nemeroff C.B. Pharmacol. Rev. 43 (1991) 425
4. McCarthy J.R., Heinrichs S.C., and Grigoriadis D.E. Curr. Pharm. Des. 5 (1999) 289
5. Dzierba C.D., Hartz R.A., and Bronson J.J. Ann. Rep. Med. Chem. 43 (2008) 3
6. Müller M.B., and Wurst W. Trends Mol. Med. 8 (2004) 409
7. Heinrichs S.C., and Taché Y. Exp. Opin. Invest. Drugs 10 (2001) 647
8. Gilligan P.J., Robertson D.W., and Zaczek R. J. Med. Chem. 43 (2000) 1641
9. Keller P.A., Elfick L., Garner J., Morgan J., and McCluskey A. Bioorg. Med. Chem. 8 (2000) 1213
10. De Souza E.B., and Grigoriadis D.E. Psychopharmacology. In: Bloom F.E., and Kupfer D.J. (Eds). The Fourth Generation of Progress (1995), Raven Press, New York 505-517
11. Dunn A.J., and Berridge C.W. Brain Res. Rev. 15 (1990) 71
12. Nemeroff C.B., Widerlov E., Bisette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., and Vale W. Science 226 (1984) 1342
13. Nemeroff C.B., Bisette G., Akil H., and Fink M. J. Psychiatry 158 (1991) 59
14. Stenzel-Poore M.P., Heinrichs S.C., Rivest R., Koob G.F., and Vale W.W. J. Neurosci. 14 (1994) 2579
15. Smith G.W., Aubry J.M., Dellu R., Contarino A., Bilezekijian L.M., Gold L.H., Chen R., Vale W., and Lee K.F. Neuron 20 (1998) 1093
16. Keller P.A., Bowman M., Dang K.H., Garner J., Leach S.P., Smith R., and McCluskey A. J. Med. Chem. 42 (1999) 2351
17. Dubowchik G.M., Michne J.A., and Zuev D. Bioorg. Med. Chem. Lett. 14 (2004) 3147
18. i values presented for all compounds are obtained as averages from determinations which were run in duplicate
19. Leone-Bay, A. U. S. Patent 4,711,962, 1987.
20. Benjes P., and Grimmett R. Heterocycles 37 (1994) 735
21. Levin J.I., Turos E., and Weinreb S.M. Synth. Commun. 12 (1982) 989
22. Grewal S.S., Shepherd J.K., Bill D.J., Fletcher A., and Dourish C.T. Psychopharmocology 133 (1997) 29